Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab

Equality Impact Assessment (Guidance development) (PDF 158 KB)

Register of interests (PDF 122 KB)

Final draft guidance

Final appraisal document (PDF 243 KB)

Committee papers (PDF 524 KB)

Public committee slides (PDF 320 KB)

Draft guidance

Appraisal consultation document (online commenting)

Committee papers (PDF 13.88 MB)

Public committee slides (PDF 990 KB)

Appraisal consultation document (PDF version) (PDF 254 KB)

Final scope (PDF 227 KB)

Final stakeholder list (PDF 299 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 226 KB)

Equality impact assessment (Scoping) (PDF 129 KB)

Provisional matrix (post-referral) (PDF 299 KB)

Consultation document draft scope (PDF 234 KB)